SBIR Phase I: AK-423: a broad-spectrum antiviral and immunomodulatory agent against COVID19

Project: Research project

Project Details

StatusFinished
Effective start/end date1/1/23 → 12/31/23

Funding

  • Akanocure Pharmaceuticals, LLC: $64,857.00